L-Tyrosine Clinical Trials

• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
  ClinicalTrials.gov Identifier: NCT00030498 - Active, not recruiting
  Cancer
  
• Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
  ClinicalTrials.gov Identifier: NCT00171912 - Recruiting
  Hypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma
  
• Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
  ClinicalTrials.gov Identifier: NCT00025675 - Active, not recruiting
  adult brain tumor
  
• ZD 1839 in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
  ClinicalTrials.gov Identifier: NCT00014170 - Active, not recruiting
  adult glioblastoma multiforme
  
• Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
  ClinicalTrials.gov Identifier: NCT00009906 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Imatinib Mesylate in Treating Patients With Gliomas
  ClinicalTrials.gov Identifier: NCT00039364 - Active, not recruiting
  adult brain tumor
  
• Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00024089 - Active, not recruiting
  Head and Neck Cancer
  
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00098631 - Active, not recruiting
  Head and Neck Cancer
  
• Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
  ClinicalTrials.gov Identifier: NCT00027690 - Active, not recruiting
  recurrent endometrial cancer
  
• Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
  ClinicalTrials.gov Identifier: NCT00096447 - Active, not recruiting
  recurrent endometrial cancer
  
• SU011248 in Treating Patients With Malignant Gastrointestinal Stromal Tumor
  ClinicalTrials.gov Identifier: NCT00085618 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Lapatinib in Treating Patients With Recurrent Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00103194 - Active, not recruiting
  recurrent prostate cancer
  
• Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
  ClinicalTrials.gov Identifier: NCT00025246 - Active, not recruiting
  gastrointestinal stromal tumor
  
• First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
  ClinicalTrials.gov Identifier: NCT00339586 - Recruiting
  Lung Neoplasms; Non-Small Cell Lung Cancer; Adenocarcinoma, Bronchiolo-Alveolar
  
• Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00096512 - Active, not recruiting
  Head and Neck Cancer
  
• Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery
  ClinicalTrials.gov Identifier: NCT00041197 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00091078 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00055770 - Active, not recruiting
  Head and Neck Cancer
  
• ZD 1839 in Treating Patients With Recurrent Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00033579 - Active, not recruiting
  recurrent prostate cancer
  
• Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
  ClinicalTrials.gov Identifier: NCT00042991 - Active, not recruiting
  untreated childhood brain stem glioma
  
• ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
  ClinicalTrials.gov Identifier: NCT00016991 - Active, not recruiting
  recurrent adult brain tumor; adult glioblastoma multiforme
  
• Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor
  ClinicalTrials.gov Identifier: NCT00062205 - Active, not recruiting
  recurrent tumors of the Ewing's family
  
• Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
  ClinicalTrials.gov Identifier: NCT00543049 - Recruiting
  Platinum Refractory Epithelial Ovarian Cancer; Primary Cancer of the Peritoneum; Cancer of the Fallopian Tube
  
• Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00087035 - Active, not recruiting
  adenocarcinoma of the prostate; recurrent prostate cancer
  
• Gefitinib in Treating Patients With Non-Small Cell Lung Cancer That Has Been Surgically Removed
  ClinicalTrials.gov Identifier: NCT00049543 - Active, not recruiting
  Non-small cell lung cancer
  
• Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00084786 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• A Study of AV-951, an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
  ClinicalTrials.gov Identifier: NCT00502307 - Recruiting
  Carcinoma, Renal Cell
  
• GW786034 in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00060151 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00068497 - Active, not recruiting
  Head and Neck Cancer; thorax and respiratory cancer
  
• Erlotinib and Tipifarnib in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00085553 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
  ClinicalTrials.gov Identifier: NCT00025116 - Active, not recruiting
  adenocarcinoma of the prostate; recurrent prostate cancer
  
• Pilot Study Using Neoadj Chemo-Rad & EGFR-Tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00243854 - Recruiting
  Pancreatic Cancer
  
• Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
  ClinicalTrials.gov Identifier: NCT00090987 - Active, not recruiting
  epidemic Kaposi's sarcoma; recurrent Kaposi's sarcoma
  
• Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Carcinosarcoma
  ClinicalTrials.gov Identifier: NCT00075400 - Active, not recruiting
  uterine carcinosarcoma; recurrent uterine sarcoma
  
• ZD6474 and Docetaxel in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00054093 - Active, not recruiting
  Non-small cell lung cancer
  
• UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00047242 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
  ClinicalTrials.gov Identifier: NCT00100945 - Active, not recruiting
  Adenocarcinoma of the Esophagus; stage II esophageal cancer
  
• Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
  ClinicalTrials.gov Identifier: NCT00052208 - Active, not recruiting
  adult glioblastoma multiforme
  
• SU011248 in Treating Women With Metastatic Breast Cancer That Did Not Respond to Anthracycline or Taxane Chemotherapy
  ClinicalTrials.gov Identifier: NCT00095615 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy
  ClinicalTrials.gov Identifier: NCT00066339 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00091299 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00068653 - Active, not recruiting
  recurrent non-small cell lung cancer
  
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00055913 - Active, not recruiting
  Head and Neck Cancer
  
• CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00098501 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
  ClinicalTrials.gov Identifier: NCT00053885 - Active, not recruiting
  advanced malignant mesothelioma; epithelial mesothelioma; recurrent malignant mesothelioma; sarcomatous mesothelioma
  
• Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
  ClinicalTrials.gov Identifier: NCT00028002 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00084708 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
  ClinicalTrials.gov Identifier: NCT00082667 - Active, not recruiting
  breast cancer in situ; intraductal breast carcinoma
  
• Study Using IMC-1121B in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy
  ClinicalTrials.gov Identifier: NCT00515697 - Recruiting
  Metastatic Renal Cell Carcinoma
  
• Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00080743 - Active, not recruiting
  recurrent breast cancer; stage IV breast cancer
  
• Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane
  ClinicalTrials.gov Identifier: NCT00059852 - Active, not recruiting
  Male Breast Cancer; recurrent breast cancer; stage IV breast cancer
  
• Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
  ClinicalTrials.gov Identifier: NCT00004227 - Active, not recruiting
  Oral Cancer; Throat Cancer
  
• Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/neu-Expressing Cancer
  ClinicalTrials.gov Identifier: NCT00084513 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00113373 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00041106 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• AZD2171 in Treating Patients With Progressive Locally Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00227760 - Active, not recruiting
  Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer
  
• Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
  ClinicalTrials.gov Identifier: NCT00087152 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Tyrosine for Methamphetamine Dependence - 1
  ClinicalTrials.gov Identifier: NCT00000322 - Completed
  Amphetamine-Related Disorders
  
• Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00041041 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/neu
  ClinicalTrials.gov Identifier: NCT00085020 - Active, not recruiting
  stage IV breast cancer; Male Breast Cancer; recurrent breast cancer
  
• Anastrozole and Gefitinib Compared With Fulvestrant and Gefitinib in Treating Postmenopausal Women With Recurrent or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00057941 - Active, not recruiting
  recurrent breast cancer; stage IV breast cancer
  
• Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
  ClinicalTrials.gov Identifier: NCT00095836 - Active, not recruiting
  anaplastic thyroid cancer; follicular thyroid cancer; medullary thyroid cancer; papillary thyroid cancer; Thyroid Cancer
  
• Imatinib Mesylate in Treating Patients With Myelofibrosis
  ClinicalTrials.gov Identifier: NCT00039416 - Active, not recruiting
  Polycythemia Vera; chronic idiopathic myelofibrosis; Essential Thrombocythemia; Chronic Myelomonocytic Leukemia
  
• Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
  ClinicalTrials.gov Identifier: NCT00128700 - Active, not recruiting
  adult glioblastoma; adult giant cell glioblastoma; adult gliosarcoma
  
• Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00103051 - Active, not recruiting
  stage IIIA non-small cell lung cancer
  
• Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00024154 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
  
• CP-724,714 in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00055926 - Active, not recruiting
  recurrent breast cancer; stage IV breast cancer; Male Breast Cancer
  
• Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00033449 - Active, not recruiting
  Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; Oropharyngeal Cancer
  
• Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
  ClinicalTrials.gov Identifier: NCT00083057 - Active, not recruiting
  Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; ...
  
• Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
  ClinicalTrials.gov Identifier: NCT00033462 - Active, not recruiting
  adult primary liver cancer; extrahepatic bile duct cancer; Gallbladder Cancer
  
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
  ClinicalTrials.gov Identifier: NCT00095563 - Active, not recruiting
  high-grade salivary gland carcinoma; low-grade salivary gland carcinoma; Salivary Gland Cancer
  
• Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
  ClinicalTrials.gov Identifier: NCT00075439 - Active, not recruiting
  Gastrinoma; gastrointestinal carcinoid tumor; Insulinoma; Islet Cell Carcinoma; metastatic gastrointestinal carcinoid tumor; ...
  
• ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00014183 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00049283 - Active, not recruiting
  Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer
  
• Erlotinib in Treating Women With Locally Advanced or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00024219 - Active, not recruiting
  stage IIIB breast cancer; stage IIIA breast cancer; stage IV breast cancer; recurrent breast cancer
  
• Erlotinib Compared With Temozolomide Or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
  ClinicalTrials.gov Identifier: NCT00086879 - Active, not recruiting
  adult glioblastoma; recurrent adult brain tumor; adult giant cell glioblastoma; adult gliosarcoma
  
• PKC412 With or Without Itraconazole in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
  ClinicalTrials.gov Identifier: NCT00045578 - Active, not recruiting
  adult acute myeloid leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes
  
• Erlotinib and Bevacizumab in Treating Women With Stage IV Breast Cancer
  ClinicalTrials.gov Identifier: NCT00054132 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
  
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
  ClinicalTrials.gov Identifier: NCT00060307 - Active, not recruiting
  recurrent renal cell cancer; Stage IV Renal Cell Cancer; stage III renal cell cancer
  
• Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
  ClinicalTrials.gov Identifier: NCT00054275 - Active, not recruiting
  recurrent breast cancer; stage IV breast cancer; Male Breast Cancer
  
• Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00088946 - Active, not recruiting
  transitional cell carcinoma of the bladder; stage 0 bladder cancer; stage I bladder cancer
  
• Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
  ClinicalTrials.gov Identifier: NCT00063895 - Active, not recruiting
  Drug Toxicity; female reproductive cancer; Head and Neck Cancer; thorax and respiratory cancer
  
• Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
  ClinicalTrials.gov Identifier: NCT00045513 - Active, not recruiting
  recurrent diffuse small lymphocytic/marginal zone lymphoma; refractory chronic lymphocytic leukemia
  
• Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
  ClinicalTrials.gov Identifier: NCT00080678 - Active, not recruiting
  adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer; bone metastases
  
• Combination Chemotherapy Plus Erlotinib in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00059787 - Active, not recruiting
  Fallopian Tube Cancer; ovarian epithelial cancer; peritoneal cavity cancer
  
• ZD6474 in Treating Patients With Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00066313 - Active, not recruiting
  extensive stage small cell lung cancer; limited stage small cell lung cancer
  
• Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
  ClinicalTrials.gov Identifier: NCT00028847 - Active, not recruiting
  chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
  
• Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
  ClinicalTrials.gov Identifier: NCT00030667 - Active, not recruiting
  Ewing's family of tumors; childhood soft tissue sarcoma; Gastrointestinal Cancer; metastatic cancer; Neuroblastoma; Osteosarcoma
  
• Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00026338 - Active, not recruiting
  stage III pancreatic cancer; adenocarcinoma of the pancreas; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00025142 - Active, not recruiting
  stage IV colon cancer; Stage IV rectal cancer; recurrent colon cancer; recurrent rectal cancer; adenocarcinoma of the colon; ...
  
• AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
  ClinicalTrials.gov Identifier: NCT00107237 - Active, not recruiting
  adult glioblastoma; recurrent adult brain tumor; adult giant cell glioblastoma; adult gliosarcoma
  
• SU011248 in Treating Patients With Metastatic Colorectal Adenocarcinoma (Cancer) That Has Not Responded to Previous Treatment With Irinotecan, Oxaliplatin, and a Fluoropyrimidine With or Without Bevacizumab
  ClinicalTrials.gov Identifier: NCT00082771 - Active, not recruiting
  stage IV colon cancer; Stage IV rectal cancer; adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent colon cancer; ...
  
• Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00062062 - Active, not recruiting
  stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer
  
• Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00101036 - Active, not recruiting
  adult primary liver cancer; extrahepatic bile duct cancer; Gallbladder Cancer; unresectable extrahepatic bile duct cancer; ...
  
• Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Treating Patients With Recurrent Late-Stage Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00091377 - Active, not recruiting
  recurrent ovarian epithelial cancer; Fallopian Tube Cancer; peritoneal cavity cancer
  
• Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer
  ClinicalTrials.gov Identifier: NCT00103324 - Active, not recruiting
  recurrent gastric cancer; stage III gastric cancer; stage IV gastric cancer; diffuse adenocarcinoma of the stomach; ...
  
• AZD2171 in Treating Patients With Locally Advanced or Metastatic Liver Cancer
  ClinicalTrials.gov Identifier: NCT00238394 - Active, not recruiting
  Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer
  
• Cetuximab, Combination Chemotherapy, and Radiation therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00109850 - Active, not recruiting
  Adenocarcinoma of the Esophagus; squamous cell carcinoma of the esophagus; stage III esophageal cancer
  
• STI571 in Treating Patients With Recurrent Leukemia
  ClinicalTrials.gov Identifier: NCT00004932 - Active, not recruiting
  recurrent childhood acute lymphoblastic leukemia; recurrent childhood acute myeloid leukemia; relapsing chronic myelogenous leukemia; ...
  
• Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00052494 - Active, not recruiting
  extensive stage small cell lung cancer; Recurrent Small Cell Lung Cancer